Skip to main content
A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study | Journal of Nuclear Medicine
Comments
Post a Comment